RxDoctor Payments DataLook up a doctor →

Douglas Eddy, MD

Internal Medicine · Rogers, ARNPI 1982961124

Payments from drug & device makers

$8,924in general payments, 2019–2025

Across 501 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AbbVie$1K
  • AstraZeneca$799
  • GSK$674
  • Pfizer$557
  • Johnson & Johnson$439
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$8,919100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,924 in reported general payments places this provider in the 90th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$255,642
Medicare patients
624
Services billed
4,342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban249$236,991
MounjaroTirzepatide202$223,422
OzempicSemaglutide131$152,193
Trelegy ElliptaFluticasone/Umeclidin/Vilanter113$98,113
JardianceEmpagliflozin69$77,905
FarxigaDapagliflozin Propanediol52$63,471
XareltoRivaroxaban48$55,821
MyrbetriqMirabegron59$44,272
WegovySemaglutide27$38,168
TrulicityDulaglutide16$29,507
VascepaIcosapent Ethyl52$26,417
JanuviaSitagliptin Phosphate26$25,431
LinzessLinaclotide25$22,627
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$18,971
Breo ElliptaFluticasone/Vilanterol25$16,154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$414$252,929218 claims
PfizerEliquis$557$236,991249 claims
Novo NordiskOzempic, Wegovy, Rybelsus$412$205,561170 claims
GSKTrelegy Ellipta, Breo Ellipta$674$114,267138 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$799$90,216104 claims
Boehringer IngelheimJardiance$319$77,90569 claims
Johnson & JohnsonXarelto$439$55,82148 claims
Astellas Pharma US IncMyrbetriq$197$44,27259 claims
MerckJanuvia, Belsomra$142$39,18060 claims
AbbVieLinzess, Synthroid$1,173$28,88083 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Rogers

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →